JPWO2021260109A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021260109A5 JPWO2021260109A5 JP2022580178A JP2022580178A JPWO2021260109A5 JP WO2021260109 A5 JPWO2021260109 A5 JP WO2021260109A5 JP 2022580178 A JP2022580178 A JP 2022580178A JP 2022580178 A JP2022580178 A JP 2022580178A JP WO2021260109 A5 JPWO2021260109 A5 JP WO2021260109A5
- Authority
- JP
- Japan
- Prior art keywords
- egfr
- combination
- use according
- compound
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 11
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 11
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 11
- 101150039808 Egfr gene Proteins 0.000 claims 8
- 229940121647 egfr inhibitor Drugs 0.000 claims 8
- 108700021358 erbB-1 Genes Proteins 0.000 claims 8
- 230000004075 alteration Effects 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 230000037430 deletion Effects 0.000 claims 4
- 238000012217 deletion Methods 0.000 claims 4
- 230000035772 mutation Effects 0.000 claims 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 4
- 231100000590 oncogenic Toxicity 0.000 claims 4
- 230000002246 oncogenic effect Effects 0.000 claims 4
- 238000006467 substitution reaction Methods 0.000 claims 4
- 230000001225 therapeutic effect Effects 0.000 claims 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 4
- 239000002552 dosage form Substances 0.000 claims 3
- -1 FCN-411 Chemical compound 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 229940125763 bromodomain inhibitor Drugs 0.000 claims 2
- ABNLUJMIBRFYRV-IHPCNDPISA-N (1S,3S)-3-[(7S)-2-benzyl-6-methoxycarbonyl-7-methyl-8,9-dihydro-7H-imidazo[4,5-f]quinolin-3-yl]cyclohexane-1-carboxylic acid Chemical compound C1[C@@H](C[C@@H](N2C3=CC=C4N(C(=O)OC)[C@H](CCC4=C3N=C2CC2=CC=CC=C2)C)CC1)C(=O)O ABNLUJMIBRFYRV-IHPCNDPISA-N 0.000 claims 1
- BFTKDWYIRJGJCA-CYBMUJFWSA-N (4R)-4-methyl-6-[1-methyl-3-(1-methylpyrazol-4-yl)indazol-5-yl]-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one Chemical compound C[C@H]1NC2=C(NC(C1)=O)C=CC=C2C=1C=C2C(=NN(C2=CC=1)C)C=1C=NN(C=1)C BFTKDWYIRJGJCA-CYBMUJFWSA-N 0.000 claims 1
- LWXLECMNBTVASW-UHFFFAOYSA-N 1-[3-[7-(difluoromethyl)-6-(1-methylpyrazol-4-yl)-3,4-dihydro-2H-quinolin-1-yl]-1-(oxan-4-yl)-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-5-yl]ethanone Chemical compound CN1C=C(C=N1)C1=CC2=C(C=C1C(F)F)N(CCC2)C1=NN(C2CCOCC2)C2=C1CN(CC2)C(C)=O LWXLECMNBTVASW-UHFFFAOYSA-N 0.000 claims 1
- LPFWVDIFUFFKJU-UHFFFAOYSA-N 1-[4-[4-(3,4-dichloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl]oxypiperidin-1-yl]prop-2-en-1-one Chemical compound C=12C=C(OC3CCN(CC3)C(=O)C=C)C(OC)=CC2=NC=NC=1NC1=CC=C(Cl)C(Cl)=C1F LPFWVDIFUFFKJU-UHFFFAOYSA-N 0.000 claims 1
- CQCWHSDMJBAGDC-UHFFFAOYSA-N 3-[7-(difluoromethyl)-6-(1-methylpyrazol-4-yl)-3,4-dihydro-2H-quinolin-1-yl]-N-methyl-1-(oxan-4-yl)-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carboxamide Chemical compound CNC(=O)N1CCc2c(C1)c(nn2C1CCOCC1)N1CCCc2cc(-c3cnn(C)c3)c(cc12)C(F)F CQCWHSDMJBAGDC-UHFFFAOYSA-N 0.000 claims 1
- GEPYBHCJBORHCE-SFHVURJKSA-N 4-[(2s)-1-[2-[2-(3-chloro-4-methoxyphenyl)ethyl]-5-(3,5-dimethyl-1,2-oxazol-4-yl)benzimidazol-1-yl]propan-2-yl]morpholine Chemical compound C1=C(Cl)C(OC)=CC=C1CCC1=NC2=CC(C3=C(ON=C3C)C)=CC=C2N1C[C@H](C)N1CCOCC1 GEPYBHCJBORHCE-SFHVURJKSA-N 0.000 claims 1
- UWXSAYUXVSFDBQ-CYBMUJFWSA-N 4-n-[3-chloro-4-(1,3-thiazol-2-ylmethoxy)phenyl]-6-n-[(4r)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]quinazoline-4,6-diamine Chemical compound C[C@@H]1COC(NC=2C=C3C(NC=4C=C(Cl)C(OCC=5SC=CN=5)=CC=4)=NC=NC3=CC=2)=N1 UWXSAYUXVSFDBQ-CYBMUJFWSA-N 0.000 claims 1
- AILRADAXUVEEIR-UHFFFAOYSA-N 5-chloro-4-n-(2-dimethylphosphorylphenyl)-2-n-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]pyrimidine-2,4-diamine Chemical compound COC1=CC(N2CCC(CC2)N2CCN(C)CC2)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1P(C)(C)=O AILRADAXUVEEIR-UHFFFAOYSA-N 0.000 claims 1
- SKDNDJWEBPQKCS-CLHVYKLBSA-N C1(F)=CC=C(N2C(=O)CCC[C@H]2C=2N(C3=CC=C(C4=C(ON=C4C)C)C=C3N=2)[C@H]2CC[C@@H](CC2)OC)C=C1F Chemical compound C1(F)=CC=C(N2C(=O)CCC[C@H]2C=2N(C3=CC=C(C4=C(ON=C4C)C)C=C3N=2)[C@H]2CC[C@@H](CC2)OC)C=C1F SKDNDJWEBPQKCS-CLHVYKLBSA-N 0.000 claims 1
- 229940126147 CCS1477 Drugs 0.000 claims 1
- 229940126010 CLN-081 Drugs 0.000 claims 1
- GHKOONMJXNWOIW-UHFFFAOYSA-N CN(CCN(C1=NC(=C(C=C1NC(C=C)=O)NC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C)OCC(F)(F)F)C)C Chemical compound CN(CCN(C1=NC(=C(C=C1NC(C=C)=O)NC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C)OCC(F)(F)F)C)C GHKOONMJXNWOIW-UHFFFAOYSA-N 0.000 claims 1
- 229940126062 Compound A Drugs 0.000 claims 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 1
- 101000726740 Homo sapiens Homeobox protein cut-like 1 Proteins 0.000 claims 1
- 101000761460 Homo sapiens Protein CASP Proteins 0.000 claims 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 1
- 239000002118 L01XE12 - Vandetanib Substances 0.000 claims 1
- USOCZVZOXKTJTI-UHFFFAOYSA-N N-[2-[2-(dimethylamino)ethyl-methylamino]-4-methoxy-5-[[4-[1-(2,2,2-trifluoroethyl)indol-3-yl]pyrimidin-2-yl]amino]phenyl]prop-2-enamide Chemical compound C(N1C2=C(C(=C1)C1=NC(=NC=C1)NC1=C(C=C(N(CCN(C)C)C)C(NC(=O)C=C)=C1)OC)C=CC=C2)C(F)(F)F USOCZVZOXKTJTI-UHFFFAOYSA-N 0.000 claims 1
- DOEOECWDNSEFDN-UHFFFAOYSA-N N-[5-[[4-(1-cyclopropylindol-3-yl)pyrimidin-2-yl]amino]-2-[2-(dimethylamino)ethyl-methylamino]-4-methoxyphenyl]prop-2-enamide Chemical compound C1(CC1)N1C=C(C2=CC=CC=C12)C1=NC(=NC=C1)NC=1C(=CC(=C(C=1)NC(C=C)=O)N(C)CCN(C)C)OC DOEOECWDNSEFDN-UHFFFAOYSA-N 0.000 claims 1
- RRMJMHOQSALEJJ-UHFFFAOYSA-N N-[5-[[4-[4-[(dimethylamino)methyl]-3-phenylpyrazol-1-yl]pyrimidin-2-yl]amino]-4-methoxy-2-morpholin-4-ylphenyl]prop-2-enamide Chemical compound CN(C)CC=1C(=NN(C=1)C1=NC(=NC=C1)NC=1C(=CC(=C(C=1)NC(C=C)=O)N1CCOCC1)OC)C1=CC=CC=C1 RRMJMHOQSALEJJ-UHFFFAOYSA-N 0.000 claims 1
- BTMKEDDEMKKSEF-QGZVFWFLSA-N N-[5-[[4-[5-chloro-4-fluoro-2-(2-hydroxypropan-2-yl)anilino]pyrimidin-2-yl]amino]-2-[(3R)-3-(dimethylamino)pyrrolidin-1-yl]-4-methoxyphenyl]prop-2-enamide Chemical compound C(C=C)(=O)NC1=C(C=C(C(=C1)NC1=NC=CC(=N1)NC1=C(C=C(C(=C1)Cl)F)C(C)(C)O)OC)N1C[C@@H](CC1)N(C)C BTMKEDDEMKKSEF-QGZVFWFLSA-N 0.000 claims 1
- MKCYPWYURWOKST-INIZCTEOSA-N NC1=NC=NC2=C1C(=C1C(=C[C@@H](CN21)NC(C=C)=O)C)C=1C=NC2=CC=CC=C2C=1 Chemical compound NC1=NC=NC2=C1C(=C1C(=C[C@@H](CN21)NC(C=C)=O)C)C=1C=NC2=CC=CC=C2C=1 MKCYPWYURWOKST-INIZCTEOSA-N 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 102100024933 Protein CASP Human genes 0.000 claims 1
- 108010086229 SYN-004 Proteins 0.000 claims 1
- MXDSJQHFFDGFDK-CYBMUJFWSA-N [4-(3-chloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl] (2r)-2,4-dimethylpiperazine-1-carboxylate Chemical compound C=12C=C(OC(=O)N3[C@@H](CN(C)CC3)C)C(OC)=CC2=NC=NC=1NC1=CC=CC(Cl)=C1F MXDSJQHFFDGFDK-CYBMUJFWSA-N 0.000 claims 1
- 229940121401 abivertinib Drugs 0.000 claims 1
- UOFYSRZSLXWIQB-UHFFFAOYSA-N abivertinib Chemical compound C1CN(C)CCN1C(C(=C1)F)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(C=CN2)C2=N1 UOFYSRZSLXWIQB-UHFFFAOYSA-N 0.000 claims 1
- 229960001686 afatinib Drugs 0.000 claims 1
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 claims 1
- 229940008421 amivantamab Drugs 0.000 claims 1
- 230000003321 amplification Effects 0.000 claims 1
- 229960003982 apatinib Drugs 0.000 claims 1
- 229950004272 brigatinib Drugs 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- LVXJQMNHJWSHET-AATRIKPKSA-N dacomitinib Chemical compound C=12C=C(NC(=O)\C=C\CN3CCCCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 LVXJQMNHJWSHET-AATRIKPKSA-N 0.000 claims 1
- 229950002205 dacomitinib Drugs 0.000 claims 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims 1
- 235000011180 diphosphates Nutrition 0.000 claims 1
- 229960001433 erlotinib Drugs 0.000 claims 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 1
- 229960002584 gefitinib Drugs 0.000 claims 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 1
- 230000037417 hyperactivation Effects 0.000 claims 1
- 229950007440 icotinib Drugs 0.000 claims 1
- QQLKULDARVNMAL-UHFFFAOYSA-N icotinib Chemical compound C#CC1=CC=CC(NC=2C3=CC=4OCCOCCOCCOC=4C=C3N=CN=2)=C1 QQLKULDARVNMAL-UHFFFAOYSA-N 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 229960004891 lapatinib Drugs 0.000 claims 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 1
- 229950009640 lazertinib Drugs 0.000 claims 1
- 229950008001 matuzumab Drugs 0.000 claims 1
- 229940015637 mobocertinib Drugs 0.000 claims 1
- ARGDYOIRHYLIMT-UHFFFAOYSA-N n,n-dichloro-4-methylbenzenesulfonamide Chemical compound CC1=CC=C(S(=O)(=O)N(Cl)Cl)C=C1 ARGDYOIRHYLIMT-UHFFFAOYSA-N 0.000 claims 1
- PJBJJXCZRAHMCK-UHFFFAOYSA-N n,n-dichlorobenzenesulfonamide Chemical compound ClN(Cl)S(=O)(=O)C1=CC=CC=C1 PJBJJXCZRAHMCK-UHFFFAOYSA-N 0.000 claims 1
- WPEWQEMJFLWMLV-UHFFFAOYSA-N n-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NC(C=C1)=CC=C1C1(C#N)CCCC1 WPEWQEMJFLWMLV-UHFFFAOYSA-N 0.000 claims 1
- 229950000908 nazartinib Drugs 0.000 claims 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 claims 1
- 229960000513 necitumumab Drugs 0.000 claims 1
- 229950008835 neratinib Drugs 0.000 claims 1
- ZNHPZUKZSNBOSQ-BQYQJAHWSA-N neratinib Chemical compound C=12C=C(NC\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZNHPZUKZSNBOSQ-BQYQJAHWSA-N 0.000 claims 1
- 229950010203 nimotuzumab Drugs 0.000 claims 1
- 238000003199 nucleic acid amplification method Methods 0.000 claims 1
- 229960003278 osimertinib Drugs 0.000 claims 1
- DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 claims 1
- 229960001972 panitumumab Drugs 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 229950009876 poziotinib Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- AZSRSNUQCUDCGG-UHFFFAOYSA-N propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate Chemical compound C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C AZSRSNUQCUDCGG-UHFFFAOYSA-N 0.000 claims 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 claims 1
- 229940048084 pyrophosphate Drugs 0.000 claims 1
- 229960000241 vandetanib Drugs 0.000 claims 1
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 claims 1
- 229950006605 varlitinib Drugs 0.000 claims 1
- 229950008250 zalutumumab Drugs 0.000 claims 1
Claims (15)
- 非小細胞肺がん(NSCLC)に罹患している患者の治療に使用するための、(i)CBP/p300ブロモドメイン阻害剤および(ii)EGFR阻害剤の組合せであって、前記NSCLCは前記EGFRに発がん性変更を呈する、組合せ。
- 前記EGFRにおける前記発がん性変更は、前記EGFRの過剰活性化をもたらす、請求項1に記載の使用のための組合せ。
- 前記発がん性変更は、EGFR遺伝子のエクソン18またはエクソン19またはエクソン20における欠失および/または挿入;EGFR遺伝子におけるキナーゼドメイン重複;EGFR遺伝子の増幅;L858R、G719S、G719A、G719C、V765A、T783A、S768I、S768V、L861Q、E709X、L819Q、A750P、およびそれらの組合せからなる群から選択され、Xは任意のアミノ酸を示すアミノ酸置換を前記EGFRにもたらすEGFR遺伝子における少なくとも1つの塩基突然変異;ならびに上述のもののいずれかの組合せにより引き起こされる、請求項1または2に記載の使用のための組合せ。
- 前記発がん性変更は、EGFR遺伝子のエクソン19における欠失、好ましくは前記EGFRにE746~A750またはL747~E749の欠失をもたらす欠失;前記EGFRにアミノ酸置換L858RまたはA750PをもたらすEGFR遺伝子における少なくとも1つの塩基突然変異;およびそれらの組合せにより引き起こされる、請求項1~3のいずれか1項に記載の使用のための組合せ。
- 但し、前記NSCLCが、EGFR阻害剤の以前の投与により前記EGFRに耐性変更をさらに呈する場合、前記組合せの前記EGFR阻害剤は、以前に投与された前記EGFR阻害剤ではない、請求項1~4のいずれか1項に記載の使用のための組合せ。
- 前記EGFRにおける前記耐性変更は、T790M、C797X、L792X、G796X、L718Q、L718V、G724S、D761Y、V834L、T854A、およびそれらの組合せからなる群から選択され、Xは任意のアミノ酸を示すアミノ酸置換を前記EGFRにもたらすEGFR遺伝子における少なくとも1つの塩基突然変異により引き起こされる、請求項5に記載の使用のための組合せ。
- 前記EGFRにおける前記耐性変更は、前記EGFRにアミノ酸置換T790MをもたらすEGFR遺伝子における少なくとも1つの塩基突然変異により引き起こされる、請求項5または6に記載の使用のための組合せ。
- 前記CBP/p300ブロモドメイン阻害剤は、化合物A、化合物C、化合物00030、化合物00071、CCS1477、GNE-781、GNE-049、SGC-CBP30、CPI-637、FT-6876、化合物462、化合物424、および化合物515からなる群から選択される、請求項1~7のいずれか1項に記載の使用のための組合せ。
- 前記EGFR阻害剤は、ABBV-321、アビベルチニブ、アファチニブ、アルフルチニブ、アルモネルチニブ、アパチニブ、AZD3759、ブリガチニブ、D0316、D0317、D0318、ダコミチニブ、DZD9008、エルロチニブ、FCN-411、ゲフィチニブ、イコチニブ、ラパチニブ、ラゼルチニブ、モボセルチニブ、ナザルチニブ、ネラチニブ、オラフェルチニブ、オシメルチニブ、ポジオチニブ、ピロチニブ、レジベルチニブ、TAS6417、バンデタニブ、バルリチニブ、XZP-5809、アミバンタマブ、CDP1、セツキシマブ、GC1118、HLX07、JMT101、M1231、ネシツムマブ、ニモツズマブ、マツズマブ、パニツムマブ、SCT200、SI-B001、SYN004、ザルツムマブ、およびそれらの組合せからなる群から選択される、請求項1~8のいずれか1項に記載の使用のための組合せ。
- 前記組合せは、各治療サイクル中に前記患者に投与される、請求項1~9のいずれか1項に記載の使用のための組合せ。
- (i)および(ii)は、別々の剤形として投与されるか、または単一の剤形に含まれている、請求項1~10のいずれか1項に記載の使用のための組合せ。
- (i)および(ii)が別々の剤形として投与される場合、各治療サイクル中の投与は、同時的または逐次的である、請求項11に記載の使用のための組合せ。
- 前記治療は、唯一の活性作用剤として投与された場合の前記EGFR阻害剤の療法効果の持続時間と比較して、療法効果の持続時間の延長をもたらす、請求項1~12のいずれか1項に記載の使用のための組合せ。
- 前記治療は、唯一の活性作用剤として投与された場合の前記EGFR阻害剤の療法有効性と比較して、療法有効性の増加をもたらす、請求項1~12のいずれか1項に記載の使用のための組合せ。
- 前記治療は、前記EGFR阻害剤に対する耐性の予防をもたらす、請求項1~12のいずれか1項に記載の使用のための組合せ。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20182364.8 | 2020-06-25 | ||
EP20182364 | 2020-06-25 | ||
EP21167277 | 2021-04-07 | ||
EP21167277.9 | 2021-04-07 | ||
PCT/EP2021/067346 WO2021260109A1 (en) | 2020-06-25 | 2021-06-24 | A COMBINATION OF A CBP/p300 BROMODOMAIN INHIBITOR AND AN EGFR INHIBITOR FOR USE IN TREATING EGFR-MUTANT NSCLC |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2023532675A JP2023532675A (ja) | 2023-07-31 |
JPWO2021260109A5 true JPWO2021260109A5 (ja) | 2024-06-19 |
Family
ID=76502741
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022580178A Pending JP2023532675A (ja) | 2020-06-25 | 2021-06-24 | EGFR突然変異NSCLCの治療に使用するための、CBP/p300ブロモドメイン阻害剤およびEGFR阻害剤の組合せ |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230255966A1 (ja) |
EP (1) | EP4171556A1 (ja) |
JP (1) | JP2023532675A (ja) |
KR (1) | KR20230028512A (ja) |
CN (1) | CN115701996A (ja) |
AU (1) | AU2021298153A1 (ja) |
BR (1) | BR112022025911A2 (ja) |
CA (1) | CA3183982A1 (ja) |
IL (1) | IL299438A (ja) |
MX (1) | MX2022016496A (ja) |
WO (1) | WO2021260109A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024130029A1 (en) * | 2022-12-15 | 2024-06-20 | Apollomics, Inc. | Treatment of cancer resistant to egfr tki using c-met inhibitor |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011085039A2 (en) | 2010-01-05 | 2011-07-14 | The Johns Hopkins University | Use of histone acetyltransferase inhibitors as novel anti-cancer therapies |
WO2013148114A1 (en) * | 2012-03-30 | 2013-10-03 | University Of Florida Research Foundation, Inc. | P300/cbp inhibitors and methods of use |
BR112016007891A2 (pt) * | 2013-10-11 | 2017-12-05 | Constellation Pharmaceuticals Inc | uso de inibidores de bromodomínio cbp/ep300 para imunoterapia do câncer |
WO2016123054A2 (en) * | 2015-01-26 | 2016-08-04 | The University Of North Carolina At Chapel Hill | Kinase drug combinations and methods of use thereof |
CN106146508A (zh) * | 2015-03-19 | 2016-11-23 | 浙江导明医药科技有限公司 | 优化的联合用药及其治疗癌症和自身免疫疾病的用途 |
GB201506658D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
KR20190040971A (ko) | 2016-07-25 | 2019-04-19 | 에피자임, 인코포레이티드 | Crebbp 관련 암 치료법 |
GB201617630D0 (en) | 2016-10-18 | 2016-11-30 | Cellcentric Ltd | Pharmaceutical compounds |
CN118021814A (zh) * | 2017-04-21 | 2024-05-14 | Epizyme股份有限公司 | 用ehmt2抑制剂进行的组合疗法 |
AU2017417160B2 (en) * | 2017-05-30 | 2024-05-02 | Deciphera Pharmaceuticals, Llc | Use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea and analogs for the treatment of cancers associated with genetic abnormalities in platelet derived growth factor receptor alpha |
BR112020001821A2 (pt) * | 2017-08-03 | 2020-07-21 | Novartis Ag | combinação terapêutica de um inibidor de tirosina quinase de egfr de terceira geração e um inibidor de quinase dependente de ciclina |
SG11201913249SA (en) * | 2017-08-03 | 2020-02-27 | Novartis Ag | Therapeutic combination of a third-generation egfr tyrosine kinase inhibitor and a raf inhibitor |
GB201806320D0 (en) | 2018-04-18 | 2018-05-30 | Cellcentric Ltd | Process |
US10870648B2 (en) | 2018-06-29 | 2020-12-22 | Forma Therapeutics, Inc. | Inhibiting CREB binding protein (CBP) |
CN110652514A (zh) * | 2018-06-29 | 2020-01-07 | 上海翰森生物医药科技有限公司 | 第三代egfr抑制剂的制药用途 |
WO2020023768A1 (en) * | 2018-07-25 | 2020-01-30 | Mayo Foundation For Medical Education And Research | Methods and materials for identifying and treating bet inhibitor-resistant cancers |
-
2021
- 2021-06-24 EP EP21733158.6A patent/EP4171556A1/en active Pending
- 2021-06-24 KR KR1020237002916A patent/KR20230028512A/ko unknown
- 2021-06-24 CN CN202180044594.4A patent/CN115701996A/zh active Pending
- 2021-06-24 CA CA3183982A patent/CA3183982A1/en active Pending
- 2021-06-24 IL IL299438A patent/IL299438A/en unknown
- 2021-06-24 AU AU2021298153A patent/AU2021298153A1/en active Pending
- 2021-06-24 US US18/012,278 patent/US20230255966A1/en active Pending
- 2021-06-24 JP JP2022580178A patent/JP2023532675A/ja active Pending
- 2021-06-24 WO PCT/EP2021/067346 patent/WO2021260109A1/en unknown
- 2021-06-24 BR BR112022025911A patent/BR112022025911A2/pt unknown
- 2021-06-24 MX MX2022016496A patent/MX2022016496A/es unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7162585B2 (ja) | Atr阻害剤による膵臓癌及び非小細胞肺癌の治療 | |
JP5167144B2 (ja) | 併用療法 | |
AU2012257727B2 (en) | Method for EGFR directed combination treatment of cancer | |
WO2020165732A1 (en) | Pharmaceutical combination comprising tno155 and a krasg12c inhibitor | |
JP2020533298A (ja) | Her誘発性薬剤耐性がんの治療又は予防のための化合物、組成物及び方法 | |
JP2020505433A5 (ja) | ||
RU2015137596A (ru) | Комбинация ингибитора EGFR T790М и ингибитора EGFR для лечения немелкоклеточного рака легкого | |
US20170304313A1 (en) | Therapeutic Combination For The Treatment Of Cancer | |
US20050222183A1 (en) | Combination of zd6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer | |
RU2014144254A (ru) | Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение | |
CA3137204A1 (en) | Quinoline compound or pharmaceutically acceptable salt thereof for treating ewing's sarcoma | |
JP2024533423A (ja) | 薬学的組成物およびその使用 | |
JP2009520787A (ja) | Azd2171およびペメトレキセドの組み合わせ | |
JP2020097588A (ja) | セリチニブとegfr阻害剤の組合せ | |
CN112043831A (zh) | 用于联合治疗乳腺癌的喹啉类化合物 | |
CA3222772A1 (en) | Erk1/2 and shp2 inhibitors combination therapy | |
AU2021267213B2 (en) | Pharmaceutical combination comprising TNO155 and nazartinib | |
KR20200036880A (ko) | 3세대 EGFR 타이로신 키나아제 억제제 및 Raf 억제제의 치료적 조합물 | |
JPWO2021260109A5 (ja) | ||
JP2019516728A (ja) | 抗がん組合せ治療 | |
CN113543784A (zh) | 用于治疗或预防癌症的喹啉衍生物 | |
Han et al. | P2. 01-21 efficacy and safety of combing anlotinib and erlotinib as a first-line therapy in patients with advanced non-small cell lung cancer (NSCLC) | |
RU2017143182A (ru) | Способы и композиции для ингибирования пути egf/egfr в комбинации с ингибиторами тирозинкиназы | |
EP1651227A1 (en) | Combination therapy | |
JPWO2021260111A5 (ja) |